Both PSR and EGAN acknowledge the importance of involving patient groups at an earl
...
Read more »
PSR is the leading expert in orphan drug development. We assist our clients to design and execute successful clinical development strategies for orphan indications. We are specialized in complex development clinical programs requiring innovative regulatory and clinical approaches.
PSR understands the challenges of developing orphan and paediatric medicines and can draw upon extensive expertise to ensure the most appropriate design of the clinical program. Having established links with physician networks, key opinion leaders, scientific advisors, government bodies and rare disease patient groups, we can ensure the best design of your clinical program.
At PSR, we have the experience to set up and run orphan studies successfully. Our project managers are familiar with managing complex, multinational studies and know how to use novel approaches to gain access to patients and maintain protocol compliance. When managing our projects we create true partnerships with our clients, investigators, key opinion leaders and all other stakeholders in the program.
03-02-2012 - PSR is part of two stage-2 FP7 applicationsPSR joined a total of two FP7 consortia for stage 2 of the 2012 FP7-HEALTH-20120-INNOVATION-1 call: preclinical an ... |
07-12-2011 - PSR to lead orphan drug MasterclassDr Anthony Hall, PSR’s Chief Medical Officer, will be leading an orphan drug Masterclass on 7th December 2011. ... |
01-02-2011 - PSR patients group EGAN sign intent to collaborateBoth PSR and EGAN acknowledge the importance of involving patient groups at an earl ... |
05-06-2010 - PSR launches new service: OrphanIQPRESS RELEASE Hoofddorp, The Netherlands, July 5, 2010 / – PSR announced today ... |